To investigate how differences in treatment parameters account for survival differences between races of patients with oropharyngeal squamous cell carcinoma (OPSCC).
Study Design
Retrospective cohort study.
Setting
National Cancer Database.
Methods
Data of patients with OPSCC undergoing radiation therapy (RT) or concurrent chemoradiation therapy as primary treatment were obtained from the National Cancer Database from 2004 to 2016. We analyzed 4 treatment-related time intervals to determine their impact on survival between races when controlling for human papilloma virus (HPV) status. Cox proportional hazards models, stepwise logistic regressions, covariate adjustments, and propensity score matching were performed.
Results
A total of 3152 patients were identified (2877 White, 275 Black). In HPV– cases, Black patients with prolonged radiation duration had a significantly worse overall survival as compared with White patients (hazard ratio, 1.77; 95% CI, 1.03-3.05; P = .039). In a logistic regression model, the only covariate that was significantly associated with prolonged RT was facility type. When further adjusted for facility type, the survival difference between Black and White patients with HPV– status and prolonged RT times was no longer significant (hazard ratio, 1.55; 95% CI, 0.90-2.69; P = .116).
Conclusions
There is a significant disparity in overall survival between Black and White patients with HPV– OPSCC when RT duration is prolonged. Clinicians should be aware of the negative impact of prolonged RT, especially in Black patients, so that they can attempt to decrease treatment-related time intervals. Facility type was also found to affect the outcomes of patients with OPSCC, and efforts should be made to improve patient access to well-equipped, high-volume facilities.
FelippuAWDFreireECSilvaRdeA, et al. Impact of delay in the diagnosis and treatment of head and neck cancer. Braz J Otorhinolaryngol. 2016;82(2):140-143. doi:10.1016/j.bjorl.2015.10.009
2.
KowalskiLPCarvalhoAL.Influence of time delay and clinical upstaging in the prognosis of head and neck cancer. Oral Oncol. 2001;37(1):94-98. doi:10.1016/s1368-8375(00)00066-x
3.
RapoportYKreitlerSChaitchikSAlgorRWeisslerK.Psychosocial problems in head-and-neck cancer patients and their change with time since diagnosis. Ann Oncol. 1993;4(1):69-73. doi:10.1093/oxfordjournals.annonc.a058365
4.
MurphyCTGallowayTJHandorfEA, et al. Increasing time to treatment initiation for head and neck cancer: an analysis of the National Cancer Database. Cancer. 2015;121(8):1204-1213. doi:10.1002/cncr.29191
5.
MurphyCTGallowayTJHandorfEA, et al. Survival impact of increasing time to treatment initiation for patients with head and neck cancer in the United States. J Clin Oncol. 2016;34(2):169-178. doi:10.1200/JCO.2015.61.5906
6.
ChenZKingWPearceyRKerbaMMackillopWJ.The relationship between waiting time for radiotherapy and clinical outcomes: a systematic review of the literature. Radiother Oncol. 2008;87(1):3-16. doi:10.1016/j.radonc.2007.11.016
7.
ShaikhTHandorfEAMurphyCTMehraRRidgeJAGallowayTJ.The impact of radiation treatment time on survival in patients with head and neck cancer. Int J Radiat Oncol Biol Phys. 2016;96(5):967-975. doi:10.1016/j.ijrobp.2016.08.046
8.
MolinaMACheungMCPerezEA, et al. African American and poor patients have a dramatically worse prognosis for head and neck cancer. Cancer. 2008;113(10):2797-2806. doi:10.1002/cncr.23889
9.
NaghaviAOEchevarriaMIStromTJ, et al. Treatment delays, race, and outcomes in head and neck cancer. Cancer Epidemiol. 2016;45:18-25. doi:10.1016/j.canep.2016.09.005
10.
ZandbergDPLiuSGoloubevaO, et al. Oropharyngeal cancer as a driver of racial outcome disparities in squamous cell carcinoma of the head and neck: 10-year experience at the University of Maryland Greenebaum Cancer Center. Head Neck. 2016;38(4):564-572. doi:10.1002/hed.23933
11.
MahalBAInversoGAizerAABruce DonoffRChuangS-K.Impact of African-American race on presentation, treatment, and survival of head and neck cancer. Oral Oncol. 2014;50(12):1177-1181. doi:10.1016/j.oraloncology.2014.09.004
12.
MurdockJMGluckmanJL.African-American and White head and neck carcinoma patients in a university medical center setting: are treatments provided and are outcomes similar or disparate?Cancer. 2001;91(1, suppl):279-283. doi:10.1002/1097-0142(20010101)91:1+<279::aid-cncr19>3.0.co;2-x
13.
NaghaviAOEchevarriaMIGrassGD, et al. Having Medicaid insurance negatively impacts outcomes in patients with head and neck malignancies. Cancer. 2016;122(22):3529-3537. doi:10.1002/cncr.30212
14.
SettleKPosnerMRSchumakerLM, et al. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in Black oropharyngeal cancer patients. Cancer Prev Res (Phila Pa). 2009;2(9):776-781. doi:10.1158/1940-6207.CAPR-09-0149
15.
ZandbergDPLiuSGoloubevaOGSchumakerLMCullenKJ.Emergence of HPV16-positive oropharyngeal cancer in Black patients over time: University of Maryland 1992-2007. Cancer Prev Res (Phila Pa). 2015;8(1):12-19. doi:10.1158/1940-6207.CAPR-14-0089-T
16.
PosnerMRLorchJHGoloubevaO, et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol. 2011;22(5):1071-1077. doi:10.1093/annonc/mdr006
17.
BlitzerGCSmithMAHarrisSLKimpleRJ.A review of the clinical and biologic aspects of HPV-positive HNC. Int J Radiat Oncol Biol Phys. 2014;88(4):761-770. doi:10.1016/j.ijrobp.2013.08.029
18.
FakhryCWestraWHWangSJ, et al. The prognostic role of sex, race, and human papillomavirus in oropharyngeal and nonoropharyngeal head and neck squamous cell cancer. Cancer. 2017;123(9):1566-1575. doi:10.1002/cncr.30353
19.
ReimersNKasperHUWeissenbornSJ, et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer. 2007;120(8):1731-1738. doi:10.1002/ijc.22355
20.
MorseEJudsonBHusainZ, et al. National treatment times in oropharyngeal cancer treated with primary radiation or chemoradiation. Oral Oncol. 2018;82:122-130. doi:10.1016/j.oraloncology.2018.02.010
21.
SharmaSBekelmanJLinA, et al. Clinical impact of prolonged diagnosis to treatment interval (DTI) among patients with oropharyngeal squamous cell carcinoma. Oral Oncol. 2016;56:17-24. doi:10.1016/j.oraloncology.2016.02.010
22.
BilimoriaKYStewartAKWinchesterDPKoCY.The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15(3):683-690. doi:10.1245/s10434-007-9747-3
23.
FarajiFRettigEMTsaiH, et al. The prevalence of human papillomavirus in oropharyngeal cancer is increasing regardless of sex or race, and the influence of sex and race on survival is modified by human papillomavirus tumor status. Cancer. 2019;125(5):761-769. doi:10.1002/cncr.31841
24.
HosokawaYShiratoHNishiokaT, et al. Effect of treatment time on outcome of radiotherapy for oral tongue carcinoma. Int J Radiat Oncol. 2003;57(1):71-78. doi:10.1016/S0360-3016(03)00507-8
25.
PlatekMEMcCloskeySACruzM, et al. Quantification of the effect of treatment duration on local-regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck. Head Neck. 2013;35(5):684-688. doi:10.1002/hed.23024
26.
PlatekMEReidMEWildingGE, et al. Pretreatment nutritional status and locoregional failure of patients with head and neck cancer undergoing definitive concurrent chemoradiation therapy. Head Neck. 2011;33(11):1561-1568. doi:10.1002/hed.21640
27.
BeseNSHendryJJeremicB.Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J Radiat Oncol. 2007;68(3):654-661. doi:10.1016/j.ijrobp.2007.03.010
28.
MackillopWJBatesJHTO’SullivanBWithersHR.The effect of delay in treatment on local control by radiotherapy. Int J Radiat Oncol. 1996;34(1):243-250. doi:10.1016/0360-3016(95)02049-7
29.
GoodwinWJThomasGRParkerDF, et al. Unequal burden of head and neck cancer in the United States. Head Neck. 2008;30(3):358-371. doi:10.1002/hed.20710
30.
GourinCGPodolskyRH.Racial disparities in patients with head and neck squamous cell carcinoma. Laryngoscope. 2006;116(7):1093-1106. doi:10.1097/01.mlg.0000224939.61503.83
31.
InversoGMahalBAAizerAADonoffRBChuangS-K.Health insurance affects head and neck cancer treatment patterns and outcomes. J Oral Maxillofac Surg. 2016;74(6):1241-1247. doi:10.1016/j.joms.2015.12.023
32.
SohnH.Racial and ethnic disparities in health insurance coverage: dynamics of gaining and losing coverage over the life-course. Popul Res Policy Rev. 2017;36(2):181-201. doi:10.1007/s11113-016-9416-y
33.
ParkHSDeckerRH.Disparities in radiation therapy delivery: current evidence and future directions in head and neck cancer. Cancers Head Neck. 2016;1(1):5. doi:10.1186/s41199-016-0005-x
34.
LenzeNRFarquharDRMazulALMasoodMMZevallosJP.Racial disparities and human papillomavirus status in oropharyngeal cancer: a systematic review and meta-analysis. Head Neck. 2019;41(1):256-261. doi:10.1002/hed.25414
35.
ShethSFarquharDRLenzeNR, et al. Decreased overall survival in Black patients with HPV-associated oropharyngeal cancer. Am J Otolaryngol. 2021;42(1):102780. doi:10.1016/j.amjoto.2020.102780
36.
WorshamMJStephenJKChenKM, et al. Improved survival with HPV among African Americans with oropharyngeal cancer. Clin Cancer Res. 2013;19(9):2486-2492. doi:10.1158/1078-0432.CCR-12-3003
37.
BoeroIJParavatiAJXuB, et al. Importance of radiation oncologist experience among patients with head-and-neck cancer treated with intensity-modulated radiation therapy. J Clin Oncol. 2016;34(7):684-690. doi:10.1200/JCO.2015.63.9898
38.
WuthrickEJZhangQMachtayM, et al. Institutional clinical trial accrual volume and survival of patients with head and neck cancer. J Clin Oncol. 2015;33(2):156-164. doi:10.1200/JCO.2014.56.5218
39.
ChenAYFedewaSPavluckAWardEM.Improved survival is associated with treatment at high-volume teaching facilities for patients with advanced stage laryngeal cancer. Cancer. 2010;116(20):4744-4752. doi:10.1002/cncr.25364
40.
SharmaASchwartzSMMéndezE.Hospital volume is associated with survival but not multimodality therapy in Medicare patients with advanced head and neck cancer. Cancer. 2013;119(10):1845-1852. doi:10.1002/cncr.27976
41.
BilimoriaKYBentremDJStewartAKWinchesterDPKoCY.Comparison of commission on cancer-approved and -nonapproved hospitals in the United States: implications for studies that use the National Cancer Data Base. J Clin Oncol. 2009;27(25):4177-4181. doi:10.1200/JCO.2008.21.7018
42.
JagsiRBekelmanJEChenA, et al. Considerations for observational research using large datasets in radiation oncology. Int J Radiat Oncol Biol Phys. 2014;90(1):11-24. doi:10.1016/j.ijrobp.2014.05.013
43.
FakhryCKrapchoMEiseleDWD’SouzaG.Head and neck squamous cell cancers in the United States are rare and risk is now higher among Whites than Blacks for the first time. Cancer. 2018;124(10):2125-2133. doi:10.1002/cncr.31322
44.
MahalBACatalanoPJHaddadRI, et al. Incidence and demographic burden of HPV-associated oropharyngeal head and neck cancers in the United States. Cancer Epidemiol Prev Biomark. 2019;28(10):1660-1667. doi:10.1158/1055-9965.EPI-19-0038
45.
TurnerMTByrdJKFerrisRL.Current role of surgery in the management of oropharyngeal cancer. J Oncol Pract. 2016;12(11):1176-1183. doi:10.1200/JOP.2016.015263
46.
WindonMJD’SouzaGFakhryC.Treatment preferences in human papillomavirus–associated oropharyngeal cancer. Future Oncol. 2018;14(24):2521-2530. doi:10.2217/fon-2018-0063
47.
CracchioloJRBaxiSSMorrisLG, et al. Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: National Cancer Data Base. Cancer. 2016;122(10):1523-1532. doi:10.1002/cncr.29938
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
